Helena Castillo-Ecija

Mrs. Helena Castillo-Ecija

Institut de Recerca Sant Joan de Déu, Barcelona
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
GPGuillem Pascual-Pasto
Guillem Pascual-Pasto
MBMiriam Bazan-Peregrino
Miriam Bazan-Peregrino
NONagore G. Olaciregui
Nagore G. Olaciregui
CRCamilo A. Restrepo-Perdomo
Camilo A. Restrepo-Perdomo
AMAna Mato-Berciano
Ana Mato-Berciano
ACAngel Carcaboso
Angel Carcaboso
Retinoblastoma is a pediatric solid tumor of the retina activated upon homozygous inactivation of the tumor suppressor RB1. VCN-01 is an oncolytic adenovirus designed to replicate selectively in tumor cells with high abundance of free E2F-1, a consequence of a dysfunctional RB1 pathway. Thus, we reasoned that VCN-01 could provide targeted therapeutic activity against even chemoresistant retinoblastoma. In vitro, VCN-01 effectively killed patient-derived retinoblastoma models. In mice, intravitreous administration of VCN-01 in retinoblastoma xenografts induced tumor necrosis, improved ocular survival compared with standard-of-care chemotherapy, and prevented micrometastatic dissemination into the brain. In juvenile immunocompetent rabbits, VCN-01 did not replicate in retinas, induced minor local side effects, and only leaked slightly and for a short time into the blood. Initial phase 1 data in patients showed the feasibility of the administration of intravitreous VCN-01 and resulted in antitumor activity in retinoblastoma vitreous seeds and evidence of viral replication markers in tumor cells. The treatment caused local vitreous inflammation but no systemic complications. Thus, oncolytic adenoviruses targeting RB1 might provide a tumor-selective and chemotherapy-independent treatment option for retinoblastoma.

15 June 2017 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MMMarina Marcet-Ortega
Marina Marcet-Ortega
SPSarai Pacheco
Sarai Pacheco
AMAna Martínez-Marchal
Ana Martínez-Marchal
HCHelena Castillo-Ecija
Helena Castillo-Ecija
EFElsa Flores
Elsa Flores
IRIgnasi Roig
Ignasi Roig
To protect germ cells from genomic instability, surveillance mechanisms ensure meiosis occurs properly. In mammals, spermatocytes that display recombination defects experience a so-called recombination-dependent arrest at the pachytene stage, which relies on the MRE11 complex—ATM—CHK2 pathway responding to unrepaired DNA double-strand breaks (DSBs). Here, we asked if p53 family members—targets of ATM and CHK2—participate in this arrest. We bred double-mutant mice combining a mutation of a member of the p53 family (p53, TAp63, or p73) with a Trip13 mutation. Trip13 deficiency triggers a recombination-dependent response that arrests spermatocytes in pachynema before they have incorporated the testis-specific histone variant H1t into their chromatin. We find that deficiency for either p53 or TAp63, but not p73, allowed spermatocytes to progress further into meiotic prophase despite the presence of numerous unrepaired DSBs. Even so, the double mutant spermatocytes apoptosed at late pachynema because of sex body deficiency; thus p53 and TAp63 are dispensable for arrest caused by sex body defects. These data affirm that recombination-dependent and sex body-deficient arrests occur via genetically separable mechanisms. Meiosis is a specialized cell division that generates haploid gametes by halving chromosome content through two consecutive rounds of chromosome segregation. At the onset of the first meiotic division, SPO11 protein introduces double-strand breaks (DSBs) throughout the genome. These DSBs are repaired through homologous recombination, which promotes pairing and synapsis of the homologous chromosomes. Some DSBs will become repaired as crossovers, providing a physical connection between the homologous chromosomes which promotes correct chromosome segregation. In fact, recombination defects can lead to formation of aneuploid gametes, one of the major causes of miscarriages and chromosome abnormalities in humans. To protect germ cells from genomic instability and to produce balanced gametes, surveillance mechanisms ensure that meiosis occurs properly. It is known that in the presence of unrepaired DSBs a control mechanism promotes a spermatogenic block at the pachytene stage. Here we describe that, downstream MRE11-ATM-CHK2 pathway, p53 and TAp63 are the effectors responsible for activating recombination-dependent arrest in mouse spermatocytes.

1 April 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PPPilar Puerto-Camacho
Pilar Puerto-Camacho
AAAna Teresa Amaral
Ana Teresa Amaral
SLSalah-Eddine Lamhamedi-Cherradi
Salah-Eddine Lamhamedi-Cherradi
BMBrian A. Menegaz
Brian A. Menegaz
HCHelena Castillo-Ecija
Helena Castillo-Ecija
ENRIQUE DE ALAVAENRIQUE DE ALAVA
ENRIQUE DE ALAVA
Purpose: Endoglin (ENG; CD105) is a co-receptor of the transforming growth factor-β (TGF-β) family that is highly expressed in proliferating endothelial cells. Often coopted by cancer cells, ENG can lead to neo-angiogenesis and vasculogenic mimicry in aggressive malignancies. It exists both as a transmembrane cell surface protein, where it primarily interacts with TGF-β, and as a soluble matricellular protein (sENG) when cleaved by matrix metalloproteinase 14 (MMP14). High ENG expression has been associated with poor prognosis in Ewing sarcoma (ES), an aggressive bone cancer that primarily occurs in adolescents and young adults. However, the therapeutic value of ENG-targeting has not been fully explored in this disease. Experimental Design: We characterized the expression pattern of transmembrane ENG, sENG and MMP14 in preclinical and clinical samples. Subsequently, the antineoplastic potential of two novel ENG-targeting monoclonal antibody-drug conjugates (ADCs), OMTX503 and OMTX703, which differed only by their drug payload (nigrin-b A chain and cytolysin, respectively), was assessed in cell lines and preclinical animal models of ES. Results: Both ADCs suppressed cell proliferation in proportion to the endogenous levels of ENG observed in vitro. Moreover, the ADCs significantly delayed tumor growth in ES cell line-derived xenografts and patient-derived xenografts (PDXs) in a dose-dependent manner. Conclusions: Taken together, these studies demonstrate potent preclinical activity of first-in-class anti-ENG ADCs as a nascent strategy to eradicate ES.

1 June 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
CMCarles Monterrubio
Carles Monterrubio
SPSonia Paco
Sonia Paco
NONagore G. Olaciregui
Nagore G. Olaciregui
GPGuillem Pascual-Pasto
Guillem Pascual-Pasto
MVMonica Vila-Ubach
Monica Vila-Ubach
ACAngel Carcaboso
Angel Carcaboso

1 April 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
ABAlexandra Bukchin
Alexandra Bukchin
GPGuillem Pascual-Pasto
Guillem Pascual-Pasto
MCMaria Cuadrado-Vilanova
Maria Cuadrado-Vilanova
HCHelena Castillo-Ecija
Helena Castillo-Ecija
CMCarles Monterrubio
Carles Monterrubio
ASALEJANDRO SOSNIK
ALEJANDRO SOSNIK

20 September 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
AZAnna Zaritski
Anna Zaritski
HCHelena Castillo-Ecija
Helena Castillo-Ecija
Murali KumarasamyMurali Kumarasamy
Murali Kumarasamy
EPElla Peled
Ella Peled
RARoni Sverdlov Arzi
Roni Sverdlov Arzi
ASALEJANDRO SOSNIK
ALEJANDRO SOSNIK